---
title: "Aprea Therapeutics gets Nasdaq extension to regain $1 minimum bid price compliance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293663219.md"
description: "Aprea Therapeutics received a Nasdaq notice granting a second 180-day extension to regain compliance with the $1 minimum bid price requirement. The new deadline is January 19, 2027. To cure the deficiency, shares must close at $1 or higher for 10 consecutive business days. Failure to meet this requirement by the deadline will trigger a delisting notice, though the company retains the right to appeal to a Nasdaq hearings panel."
datetime: "2026-07-23T20:27:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293663219.md)
  - [en](https://longbridge.com/en/news/293663219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293663219.md)
generator: "portal-rs"
---

# Aprea Therapeutics gets Nasdaq extension to regain $1 minimum bid price compliance

-   Aprea Therapeutics received a Nasdaq notice granting a second 180-day window to regain $1 minimum bid-price compliance. \* The new deadline is Jan. 19, 2027; shares must close at $1 or higher for 10 consecutive business days to cure. \* Failure to regain compliance by the deadline triggers a delisting notice; the company can appeal to a Nasdaq hearings panel. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-086254), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)

## Related News & Research

- [Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | APRE Stock News](https://longbridge.com/en/news/297324671.md)
- [Scanfil expands integration, testing capacity with new MB Elettronica Plant 6 in Italy](https://longbridge.com/en/news/297637889.md)
- [Topsoe wins Uniper contract for Sweden e-methanol project FEED work](https://longbridge.com/en/news/297483209.md)
- [Honda Motor Co - Nissan And Honda Conclude Joint Development Agreement To Standardize Ecus And Software For Next-Generation Sdvs](https://longbridge.com/en/news/297481998.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**